- Home
- UWMC vs TYRA Comparison
UWMC vs TYRA Comparison
Compare UWMC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- TYRA
- Stock Information
- Founded
- UWMC 1986
- TYRA 2018
- Country
- UWMC United States
- TYRA United States
- Employees
- UWMC N/A
- TYRA N/A
- Industry
- UWMC Finance: Consumer Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- TYRA Health Care
- Exchange
- UWMC Nasdaq
- TYRA Nasdaq
- Market Cap
- UWMC 911.2M
- TYRA 819.3M
- IPO Year
- UWMC N/A
- TYRA 2021
- Fundamental
- Price
- UWMC $6.22
- TYRA $15.91
- Analyst Decision
- UWMC Hold
- TYRA Strong Buy
- Analyst Count
- UWMC 8
- TYRA 6
- Target Price
- UWMC $7.34
- TYRA $30.50
- AVG Volume (30 Days)
- UWMC 4.1M
- TYRA 261.4K
- Earning Date
- UWMC 02-26-2025
- TYRA 03-18-2025
- Dividend Yield
- UWMC 6.43%
- TYRA N/A
- EPS Growth
- UWMC N/A
- TYRA N/A
- EPS
- UWMC N/A
- TYRA N/A
- Revenue
- UWMC $2,727,467,000.00
- TYRA N/A
- Revenue This Year
- UWMC $3.72
- TYRA N/A
- Revenue Next Year
- UWMC $24.09
- TYRA N/A
- P/E Ratio
- UWMC N/A
- TYRA N/A
- Revenue Growth
- UWMC 29.95
- TYRA N/A
- 52 Week Low
- UWMC $5.31
- TYRA $12.34
- 52 Week High
- UWMC $9.74
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- UWMC 57.97
- TYRA 52.83
- Support Level
- UWMC $5.31
- TYRA $15.75
- Resistance Level
- UWMC $6.28
- TYRA $17.27
- Average True Range (ATR)
- UWMC 0.27
- TYRA 0.91
- MACD
- UWMC 0.09
- TYRA 0.20
- Stochastic Oscillator
- UWMC 93.31
- TYRA 65.99
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale and servicing of residential mortgage loans. The company provides independent mortgage advisors across the states and the district of Columbia.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).